Migraines can significantly reduce the quality of life of those affected. Early treatment is therefore advisable if the diagnosis is confirmed. Migraine therapy can be divided into three groups: Acute therapy, prophylaxis, non-drug measures. Monoclonal antibodies against CGRP and the CGRP receptor are now well established for long-term drug prophylaxis. The new up-and-coming generation of migraine drugs includes Ditane and Gepante.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Plea for sex-specific neurology
Migraine in men: underdiagnosed, underestimated, under-researched
- Prurigo nodularis
Retrospective analyses of large data sets from everyday practice
- Public Health
Outpatient care in Switzerland: situation report
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer
Tuberculosis vaccination reduces recurrences
- Oral JAK-i in atopic dermatitis
Benefits and risks: What does the current data say?
- Sleep-wake disorders in pneumology practice